| Literature DB >> 31106135 |
Sam Paul1, Rupshikha Choudhury2, Nandini Kumari3, Sanjay Rastogi4, Ashish Sharma4, Vikas Singh5, Shyamalendu Laskar4, Tushar Dubey4.
Abstract
OBJECTIVES: To appraise the effectiveness of platelet-rich fibrin (PRF) in the management of established dry socket in terms of pain, inflammation, and wound healing.Entities:
Keywords: Dry socket; Pain; Platelet-rich fibrin; Wound healing
Year: 2019 PMID: 31106135 PMCID: PMC6502748 DOI: 10.5125/jkaoms.2019.45.2.76
Source DB: PubMed Journal: J Korean Assoc Oral Maxillofac Surg ISSN: 1225-1585
Preoperative evaluation criteria
| Pain | Degree of inflammation | Exposed bone | |
|---|---|---|---|
| Method | VAS | Clinical assessment | No. of socket walls exposed |
| Score | 1-10 | 1: mild | 1: one wall |
| 2: moderate | 2: two walls | ||
| 3: severe | 3: three walls | ||
| 4: four walls |
(VAS: visual analogue scale)
Postoperative evaluation criteria
| Pain | No. of packs | Criteria for healing | |
|---|---|---|---|
| Method | VAS | Clinical assessment | Clinical assessment |
| Score | 1-10 | Actual no. of patient visits | 4: four walls |
| 3: three walls | |||
| 2: two walls | |||
| 1: one wall | |||
| 0: zero walls |
(VAS: visual analogue scale)
Fig. 1Flow diagram for patient recruitment and selection. (PRF: platelet-rich fibrin, ZOE: zinc oxide eugenol)
Primary outcome variables
| Postoperative day | Pain | Inflammation | Exposed bone | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Group A | Group B | Group A | Group B | Group A | Group B | ||||
| 1st | 4.57 | 6.15 | <0.001* | 96.9 | 104.1 | 0.450 | 2.62 | 3.02 | <0.001* |
| 3rd | 2.38 | 3.85 | <0.001* | 91.5 | 109.5 | <0.001* | 1.60 | 1.97 | <0.001* |
| 7th | 0 | 1.70 | <0.001* | 82.5 | 0118.5 | <0.001* | 0.60 | 0.83 | <0.001* |
| 14th | 0 | 1.20 | <0.001* | 35.6 | 68.7 | <0.001* | 0.20 | 0.55 | <0.001* |
(Group A: platelet-rich fibrin, Group B: zinc oxide eugenol)
*P<0.05.
Values are presented as mean.
Fig. 2Visual analogue scale (VAS) for pain at 1st, 3rd, 7th, and 14th day. Values are presented as mean. (Group A: platelet-rich fibrin, Group B: zinc oxide eugenol)
Secondary outcome variables
| Variable | Value | ||
|---|---|---|---|
| Age (yr) | 18-40 | ||
| Sex | Male | Female | |
| Group A | 38.9 | 61.1 | |
| Group B | 42.1 | 57.9 | |
| 0.008* | <0.001* | ||
| Site | Maxilla | Mandible | |
| Group A | 24.2 | 75.7 | |
| Group B | 22.1 | 77.8 | |
| 0.003* | 0.003* | ||
| Rescue medications | Medication | Non-medication | |
| Group A | 0 | 95 | |
| Group B | 95 | 0 | |
| <0.001* | <0.001* | ||
(Group A: platelet-rich fibrin, Group B: zinc oxide eugenol)
*P<0.05.
Values are presented as %.
Fig. 3Presence or absence of inflammation on 1st, 3rd, 7th, and 14th day. Values are presented as mean. (Group A: platelet-rich fibrin, Group B: zinc oxide eugenol)
Fig. 4Assessment of bone healing through number of exposed walls on 1st, 3rd, 7th, and 14th day. Values are presented as mean. (Group A: platelet-rich fibrin, Group B: zinc oxide eugenol)